We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

115 hedge funds and large institutions have $208M invested in Lineage Cell Therapeutics in 2021 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 34 increasing their positions, 15 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

127% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 15

65% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 20

59% more call options, than puts

Call options by funds: $818K | Put options by funds: $514K

47% more capital invested

Capital invested by funds: $142M → $208M (+$66.6M)

13% more funds holding

Funds holding: 102 → 115 (+13)

7.8% more ownership

Funds ownership: 37.32% → 45.12% (+7.8%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
115
Holders Change
+13
Holders Change %
+12.75%
% of All Funds
2%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
33
Increased
34
Reduced
15
Closed
20
Calls
$818K
Puts
$514K
Net Calls
+$304K
Net Calls Change
+$492K

Top Buyers

1
BlackRock
BlackRock
New York
+$15.7M
2
JP Morgan Chase
JP Morgan Chase
New York
+$5.05M
3
State Street
State Street
Massachusetts
+$4.66M
4
Northern Trust
Northern Trust
Illinois
+$3.45M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$2.78M

Top Sellers

1
Millennium Management
Millennium Management
New York
-$3.35M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.4M
3
ECM
ExodusPoint Capital Management
New York
-$785K
4
HF
HRT Financial
New York
-$679K
5
Goldman Sachs
Goldman Sachs
New York
-$479K
Name Holding Trade Value Shares
Change 		Change in
Stake
VPI
26
Value Partners Investments
Manitoba, Canada
$342K +$311K +120,000 New
RhumbLine Advisers
27
RhumbLine Advisers
Massachusetts
$321K +$291K +112,515 New
New York State Common Retirement Fund
28
New York State Common Retirement Fund
New York
$296K +$269K +103,900 New
Manulife (Manufacturers Life Insurance)
29
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$222K +$202K +78,044 New
Citadel Advisors
30
Citadel Advisors
Florida
$212K -$403K -155,914 -68%
DA
31
DCF Advisers
Connecticut
$212K +$138K +53,500 +255%
Susquehanna International Group
32
Susquehanna International Group
Pennsylvania
$207K -$2.4M -927,463 -93%
Deutsche Bank
33
Deutsche Bank
Germany
$205K +$186K +71,992 New
SWIG
34
Strategic Wealth Investment Group
Kentucky
$183K -$988 -382 -0.6%
LPL Financial
35
LPL Financial
California
$172K +$33K +12,746 +27%
Commonwealth Equity Services
36
Commonwealth Equity Services
Massachusetts
$154K +$15.6K +6,014 +12%
VF
37
Virtu Financial
New York
$154K +$140K +54,131 New
WG
38
Winton Group
United Kingdom
$153K +$24.8K +9,596 +22%
T. Rowe Price Associates
39
T. Rowe Price Associates
Maryland
$153K +$25.7K +9,931 +23%
APA
40
American Portfolios Advisors
New York
$152K – – –
Simplex Trading
41
Simplex Trading
Illinois
$146K -$52.3K -20,227 -28%
MIM
42
MetLife Investment Management
New Jersey
$144K +$131K +50,559 New
FSA
43
Fort Sheridan Advisors
Illinois
$137K +$7.76K +3,000 +7%
VOYA Investment Management
44
VOYA Investment Management
Georgia
$137K +$124K +47,970 New
CSS
45
Cubist Systematic Strategies
Connecticut
$135K -$249K -96,200 -67%
BWCS
46
Beirne Wealth Consulting Services
Connecticut
$128K – – –
Invesco
47
Invesco
Georgia
$126K +$115K +44,447 New
RA
48
Raffles Associates
New York
$124K – – –
Thrivent Financial for Lutherans
49
Thrivent Financial for Lutherans
Minnesota
$121K +$110K +42,670 New
MLICM
50
Metropolitan Life Insurance Company (MetLife)
New York
$110K +$100K +38,709 New
1
2
3 4 5

LCTX Hedge Fund Activity: Q2 2021 in Review

115 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2021, worth a combined $208M — up 47% from $142M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new LCTX positions and 20 closed out — a net gain of 13 holders — while 34 added to existing stakes and 15 trimmed.

The largest buyer was BlackRock, adding an estimated $15.7M. The largest seller was Millennium Management, exiting entirely with an estimated $3.35M sold.

  • 115 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2021, up from 102 in Q1 2021.
  • Funds reported $208M of Lineage Cell Therapeutics stock for Q2 2021, up 47% quarter-over-quarter.
  • 33 funds opened new Lineage Cell Therapeutics positions in Q2 2021 and 20 closed out, a net change of +13 holders.
  • The largest Lineage Cell Therapeutics buyer in Q2 2021 was BlackRock, an estimated $15.7M added.
  • The largest Lineage Cell Therapeutics seller in Q2 2021 was Millennium Management, an estimated $3.35M sold.

Based on aggregated 13F filings for Q2 2021.